New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
07:41 EDTSNYSanofi R&D focused on biology of disease, WSJ reports
Dr. Elias Zerhouni, a former director of the U.S. National Institutes of Health, and now head of R&D at Sanofi (SNY) is attempting to shift to an earlier stage of research and development, and boost the number and quality of the company's drug discoveries. He has recruited about 20 new R&D leaders to help Sanofi become better at understanding how diseases work and how to target them. "We're investing a lot more upstream in understanding human-disease biology," he says. "We're extremely good at toolmaking," he added, referring to the formulation of new pills and shots, "but not very good at understanding the biology" of disease.Reference Link
News For SNY From The Last 14 Days
Check below for free stories on SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
13:40 EDTSNYFDA expands approval of Lumizyme
Subscribe for More Information
July 31, 2014
19:08 EDTSNYSanofi raises stake in Regeneron to 22.5% from 21.6%
Subscribe for More Information
05:56 EDTSNYSanofi reports Q2 business net income up 13% to EUR 1.54B
Subscribe for More Information
July 30, 2014
16:31 EDTSNYRegeneron, Sanofi announce plan to use priority review voucher for alirocumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the companies intend to use a FDA rare pediatric disease priority review voucher in connection with the Biologics License Application, or BLA, submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited 6-month review from the filing date instead of the standard 10-month review. Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, purchased the voucher from BioMarin GALNS, a direct, wholly-owned subsidiary of BioMarin Pharmaceutical (BMRN), which had received it through the FDA's rare pediatric disease priority review voucher program. Sanofi and Regeneron will equally share the purchase price of $67.5M. Sanofi and Regeneron expect to submit U.S. and EU regulatory submissions for alirocumab before year end.
12:33 EDTSNYRegeneron, Sanofi likely to file alirocumab BLA this year, says Piper Jaffray
Subscribe for More Information
08:08 EDTSNYSanofi and Regeneron report positive Phase 2 results of alirocumab
Subscribe for More Information
July 28, 2014
09:02 EDTSNYSanofi, InnerWorkings sign global marketing partnership
Subscribe for More Information
July 21, 2014
07:11 EDTSNYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use